If you want to know who really controls Gossamer Bio, Inc. (NASDAQ:GOSS), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company ...

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other ...

Goldman Sachs analyst Paul Choi maintained a Buy rating on Gossamer Bio (GOSS – Research Report) today and set a price target of $9.00. Paul Choi has given his Buy rating due to a combination of ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20250313732742/en/ For Investors and Media: Bryan Giraudo, Chief Financial Officer ...

Following its presentation at the ATS 2025 International Conference, the poster will also be made available on the “Posters & Publications” section of the ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20250805169625/en/ The articles, information, and content displayed on this webpage ...

- Gossamer to Present Preclinical Evidence of Synergistic Treatment Effect from Combination Seralutinib & Sotatercept in Models of PAH - “Gossamer is committed to generating and presenting data that ...

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20240812706587/en/ For Investors and Media: Bryan Giraudo, Chief Operating Officer and ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary ...